US 11,911,511

Application 17/201,811 · Granted Feb 27, 2024

Anticancer compositions

Estimated expiration

December 3, 2035

9y 14d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Dec 3, 2015
+ 20 years
Dec 3, 2035
PTA +360d
Nov 27, 2036
TD cap (US 10,285,948)
Dec 3, 2035
Final
Dec 3, 2035

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
March 15, 2021
Earliest effective filing
December 3, 2015
Issue date
February 27, 2024
PTA
+360 days
Base expiry (before PTA)
December 3, 2035

December 3, 2015 + 20 years = December 3, 2035 + 360 PTA days = November 27, 2036

  • Continuation of application 16/357,821, filed Mar 19, 2019, issued as US 11,224,575
  • Continuation of application 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
  • National stage entry of application PCTUS2015063671, filed Dec 3, 2015
  • National stage entry of application PCTUS2015063671, filed Dec 3, 2015
  • Continuation of application 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
  • National stage entry of application PCTUS2015063671, filed Dec 3, 2015

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to December 3, 2035 (earliest expiring referenced patent: US 10,285,948)

  • US 3,693,002

    Could not resolve calculation details

  • US 10,285,948· Application 15/533,229Capping patent

    Anticancer compositions

    Filing date
    Jun 5, 2017
    Earliest effective filing
    Dec 3, 2015
    Issue date
    May 14, 2019
    PTA
    0 days
    Calculated expiration
    Dec 3, 2035

    National stage entry of PCTUS2015063671, filed Dec 3, 2015

    Dec 3, 2015 + 20y = Dec 3, 2035

  • US 11,224,575· Application 16/357,821

    Anticancer compositions

    Filing date
    Mar 19, 2019
    Earliest effective filing
    Dec 3, 2015
    Issue date
    Jan 18, 2022
    PTA
    0 days
    Calculated expiration
    Dec 3, 2035

    Continuation of 15/533,229, filed Jun 5, 2017, issued as US 10,285,948

    National stage entry of PCTUS2015063671, filed Dec 3, 2015

    National stage entry of PCTUS2015063671, filed Dec 3, 2015

    Dec 3, 2015 + 20y = Dec 3, 2035

  • US 11,911,511· Application 17/201,811(from application 17/201,811)

    Anticancer compositions

    Filing date
    Mar 15, 2021
    Earliest effective filing
    Dec 3, 2015
    Issue date
    Feb 27, 2024
    PTA
    +360 days
    Calculated expiration
    Nov 27, 2036

    Continuation of 16/357,821, filed Mar 19, 2019, issued as US 11,224,575

    Continuation of 15/533,229, filed Jun 5, 2017, issued as US 10,285,948

    National stage entry of PCTUS2015063671, filed Dec 3, 2015

    National stage entry of PCTUS2015063671, filed Dec 3, 2015

    Continuation of 15/533,229, filed Jun 5, 2017, issued as US 10,285,948

    National stage entry of PCTUS2015063671, filed Dec 3, 2015

    Dec 3, 2015 + 20y + 360d PTA = Nov 27, 2036

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/201,811 · US 11,911,511

PatentReply compiles the prosecution history behind US 11,911,511: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11911511

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.